No annual revenue total was found in CABALETTA BIO, INC.'s SEC filings.
Cabaletta Bio, Inc. (CABA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$132.3 million. As of Sep 30, 2026 it held $299.4 million in cash and investments and $23.2 million in total debt.
Revenue
—
Net income (TTM)
$-189.50M
-19.5% vs year-ago TTM
Operating cash flow (TTM)
$-162.16M
-36.4% vs year-ago TTM
Free cash flow (TTM)
$-162.51M
-35.1% vs year-ago TTM
EPS
$-2.10
+10.3% vs prior year
Dividend per share
$0.00
Shares outstanding
111.32M
+119.4% vs prior year
Net cash
$276.21M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CABA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Philadelphia, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1759138
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$172.2M | -$125.1M | -$74.7M | -$54.1M | -$46.3M |
| Net income | -$167.9M | -$115.9M | -$67.7M | -$53.0M | -$46.3M |
| Diluted EPS | -$2.10 | -$2.34 | -$1.65 | -$1.81 | — |
| Operating cash flow | -$131.1M | -$88.2M | -$53.5M | -$46.4M | -$34.1M |
| Free cash flow | -$132.3M | -$90.4M | -$54.2M | -$48.8M | -$35.3M |
| Total assets | $165.1M | $185.0M | $253.7M | $117.0M | $126.3M |
| Total liabilities | $53.0M | $32.7M | $17.5M | $12.4M | — |
| Stockholders' equity | $112.1M | $152.3M | $236.2M | $104.5M | $118.0M |
| Cash and investments | $133.6M | $164.0M | $241.2M | $106.5M | $122.2M |
| Total debt | $27.1M | $15.6M | $5.0M | $1.5M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 11, 2026 | Jun 9, 2026 |
All 448 Cabaletta Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.